Journal of Endodontics
Volume 33, Issue 11 , Pages 1304-1308 , November 2007

Effect of an Estrogen-deficient State and Alendronate Therapy on Bone Loss Resulting from Experimental Periapical Lesions in Rats

  • Haofei Xiong, DDS, PhD
    • ,
  • Bin Peng, DDS, PhD

      Affiliations

    • Corresponding Author InformationAddress requests for reprints to Dr Bin Peng, Key Lab for Oral Biomedical Engineering of Mininstry of Education, School and Hospital of Stomatology, Wuhan University, 237 Luoyu Road, Wuhan, Hubei 430079, China.
    • ,
  • Lili Wei, DDS, PhD
    • ,
  • Xiaolei Zhang, DDS, PhD
    • ,
  • Li Wang, DDS, PhD

References 

  1. Hofbauer LC, Kühne CA, Viereck V. The OPG/RANKL/RANK system in metabolic bone disease. J Musculoskel Neuron Interact. 2004;4:268–275
  2. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21:115–137
  3. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res. 1996;11:1043–1051
  4. Riggs BL, Khosla S, Melton LJ. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 1998;13:763–773
  5. Jiang G, Matsumoto H, Fujii A. Mandible bone loss in osteoporosis rats. J Bone Miner Metab. 2003;21:388–395
  6. Gilles JA, Carnes DL, Dallas MR, et al. Oral bone loss is increased in ovariectomized rats. J Endod. 1997;23:419–422
  7. Duarte PM, Goncalves PF, Sallum AW, et al. Effect of an estrogen-deficient state and its therapy on bone loss resulting from an experimental periodontitis in rats. J Periodont Res. 2004;39:107–110
  8. Seedor JG, Quartucci HA, Thompson DD. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res. 1991;6:339–346
  9. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437–1443
  10. Duarte PM, de Assis DR, Casati MZ, et al. Alendronate may protect against increased periodontitis-related bone loss in estrogen-deficient rats. J Periodontol. 2004;75:1196–1202
  11. Lane N, Armitage GC, Loomer P, et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol. 2005;76:1113–1122
  12. Metzger Z, Klein H, Klein A, et al. Periapical lesion development in rats inhibited by dexamethasone. J Endod. 2002;28:643–645
  13. Lin SK, Hong CY, Chang HH, et al. Immunolocalization of macrophages and transforming growth factor-β1 in induced rat periapical lesions. J Endod. 2000;26:335–340
  14. Balto K, Mŭller R, Carrington DC, et al. Quantification of periapical bone destruction in mice by micro-computed tomography. J Den Res. 2000;79:35–40
  15. Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int. 1982;34:285–290
  16. Nociti FH, Sallum AW, Duarte PM, et al. Effect of estrogen replacement and calcitonin therapies on bone around titanium implants placed in ovariectomized rats: A histometric study. Int J Oral Maxillofac Implants. 2002;17:786–792
  17. Durate PM, Goncalves PF, Casati MZ, et al. Estrogen and alendronate therapies may prevent the influence of estrogen deficiency on the tooth-supporting alveolar bone: a histometric study in rats. J Periodont Res. 2006;41:541–546
  18. Razmus TF. Caries, periodontal disease, and periapical changes. Dent Clin North Am. 1994;38:13–31
  19. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999;20:345–357
  20. Takayanagi H, Ogasawara K, Hida S, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature. 2000;408:600–605
  21. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309–319
  22. Zhang XL, Peng B. Immunolocalization of receptor activator of NF kappa B ligand in rat periapical lesions. J Endod. 2005;31:574–577
  23. Chapurlat RD, Delmas PD. Drug insight: bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab. 2006;2:211–219
  24. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13:581–589
  25. Benford HL, McGowan NW, Helfrich MH, et al. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone. 2001;28:465–473
  26. Katz H. Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: a report of three cases. J Endod. 2005;31:831–834
  27. Sarathy AP, Bourgeois SL, Goodell GG, et al. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Endod. 2005;31:759–763
  28. Aki S, Eskiyurt N, Akarimak U, et al. Gastroinstestinal side effect profile duo to the use of alendronate in the treatment of osteoporosis. Yonsei Med J. 2003;44:961–967

PII: S0099-2399(07)00638-3

doi: 10.1016/j.joen.2007.07.011

Journal of Endodontics
Volume 33, Issue 11 , Pages 1304-1308 , November 2007

Article Tools

* Image Usage & Resolution